Related Experiment Video
Updated: May 27, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Selection and optimization of asymmetric siRNA targeting the human c-MET gene
Seul-gi Jo1, Sun Woo Hong, Jae Wook Yoo
1Global Research Laboratory for RNAi Medicine, Department of Chemistry and Brain Korea 21 School of Chemical Materials Science, Sungkyunkwan University, Suwon 440-746, Korea.
Abstract:
The silencing of specific oncogenes via RNA interference (RNAi) holds great promise for the future of cancer therapy. RNAi is commonly carried out using small interfering RNA (siRNA) composed of a 19 bp duplex region with a 2-nucleotide overhang at each 3' end. This classical siRNA structure, however, can trigger non-specific effects, which has hampered the development of specific and safe RNAi therapeutics. Previously, we developed a novel siRNA structure, called asymmetric shorter-duplex siRNA (asiRNA), which did not cause the non-specific effects triggered by conventional siRNA, such as off-target gene silencing mediated by the sense strand. In this study, we first screened potent asiRNA molecules targeting the human c-MET gene, a promising anticancer target. Next, the activity of a selected asiRNA was further optimized by introducing a locked nucleic acid (LNA) to maximize the gene silencing potency. The optimized asiRNA targeted to c-MET may have potential as a specific and safe anticancer RNAi therapeutic.
Insights
Asymmetric shorter-duplex siRNA (asiRNA) offers a safer alternative to conventional siRNA for cancer therapy by avoiding off-target gene silencing. Optimized asiRNA targeting c-MET shows potential as a specific and effective anticancer treatment.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- RNA interference (RNAi) using small interfering RNA (siRNA) is a promising cancer therapy strategy.
- Conventional siRNA structures can cause non-specific effects, hindering therapeutic development.
- Asymmetric shorter-duplex siRNA (asiRNA) was previously developed to mitigate these non-specific effects.
Purpose of the Study:
- To screen potent asiRNA molecules targeting the human c-MET oncogene.
- To optimize asiRNA activity for enhanced gene silencing potency.
- To evaluate the potential of optimized asiRNA as a specific and safe anticancer therapeutic.
Main Methods:
- Screening of asiRNA molecules targeting the human c-MET gene.
- Optimization of asiRNA by incorporating locked nucleic acid (LNA) modifications.
- Assessment of gene silencing activity and specificity of the optimized asiRNA.
Main Results:
- Identification of potent asiRNA molecules targeting c-MET.
- Enhanced gene silencing potency achieved through LNA modification.
- The optimized asiRNA demonstrated specificity and reduced non-specific effects.
Conclusions:
- Optimized asiRNA targeting c-MET is a potential next-generation RNAi therapeutic.
- asiRNA technology offers improved safety and specificity for cancer treatment.
- Further development of asiRNA could lead to effective and targeted cancer therapies.
More Related Videos
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
10:21Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
Published on: January 5, 2018